Citius Oncology Inc Quick Ratio (TENKU) starting from the third quarter 2026 to third quarter 2025, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Citius Oncology Inc  (NASDAQ: TENKU)

Citius Oncology Inc's Quick Ratio

TENKU's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Citius Oncology Inc's Cash & cash equivalent grew by 529.17 % in the Q3 2026 sequentially, while Current Liabilities decreased, this led to improvement in Citius Oncology Inc's Quick Ratio to 0.5, Quick Ratio remained below Citius Oncology Inc average.

Within Major Pharmaceutical Preparations industry 389 other companies have achieved higher Quick Ratio than Citius Oncology Inc in third quarter 2026. While Quick Ratio total ranking has improved so far during the Q3 2026 to 2447, from total ranking in the second quarter 2026 at 3417.

Explain Quick Ratio?
How much Cash & cash equivalents TENKU´s has?
What are TENKU´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

TENKU Quick Ratio (Jun 30 2026)
Q3		 (Mar 31 2026)
Q2		 (Dec 31 2025)
2025		 (Sep 30 2025)
Q4		 (Jun 30 2025)
Q3
Y / Y Current Liabilities Change -37.44 % 18.24 % 3.02 % 1233.43 % 1622.76 %
Y / Y Cash & cash equivalent Change - 2350466.07 % 6513695.54 % - -
Quick Ratio MRQ 0.5 0.04 0.16 - -
TENKU's Total Ranking # 2447 # 3417 # 1694 # 0 # 0
Seq. Current Liabilities Change -43.63 % 31.54 % -9.66 % -6.6 % 6.53 %
Seq. Cash & cash equivalent Change 529.17 % -63.91 % - - -



Quick Ratio third quarter 2026 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 390
Healthcare Sector # 735
Overall Market # 2447


Quick Ratio Statistics
High Average Low
6018.8 501.7 0
(Mar 31 2023)   (Mar 31 2025)




Financial Statements
Citius Oncology Inc's Current Liabilities $ 33 Millions Visit TENKU's Balance sheet
Citius Oncology Inc's Cash & cash equivalent $ 17 Millions Visit TENKU's Balance sheet
Source of TENKU's Sales Visit TENKU's Sales by Geography


Cumulative Citius Oncology Inc's Quick Ratio

TENKU's Quick Ratio for the trailling 12 Months

TENKU Quick Ratio

 (Jun 30 2026)
12 Months		 (Mar 31 2026)
12 Months		 (Dec 31 2025)
12 Months		 (Sep 30 2025)
12 Months		 (Jun 30 2025)
12 Months
Y / Y Current Liabilities TTM Growth 24.24 % 106.15 % 271.53 % 1578.82 % 1545.83 %
Y / Y Cash & cash equivalent TTM Growth 8176378.4 % 1697008.55 % 21482.59 % -99.66 % -99.65 %
Quick Ratio TTM 0.14 0.05 0.04 0 0
Total Ranking TTM # 4151 # 4146 # 3186 # 3321 # 2184
Seq. Current Liabilities TTM Growth -9.63 % 4.61 % 0.67 % 30.55 % 49.95 %
Seq. Cash & cash equivalent TTM Growth 166.84 % 36.08 % 3256847.77 % -30.86 % -44.62 %

Quick ratio ranking by company, industry and sector >> Back to TENKU Financial Strength Comparisons >> Go to Compare TENKU Quick Ratio to its Competitors

On the trailing twelve months basis TENKU Cash & cash equivalent more than doubled by 529.17 % in Q3 2026 year on year, while Current Liabilities plummeted to $33 millions, this led to increase in in Citius Oncology Inc's Quick Ratio to 0.14, Quick Ratio remained below TENKU average.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 443 other companies have achieved higher Quick Ratio than Citius Oncology Inc. While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the second quarter 2026 from 4146 to 4151.

Explain Quick Ratio?
How much Cash & cash equivalents TENKU´s has?
What are TENKU´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 444
Healthcare Sector # 916
Within the Market # 4151


trailing twelve months Quick Ratio Statistics
High Average Low
1.08 0.22 0
(Mar 31 2023)   (Sep 30 2025)




Companies with similar Quick Ratio in the quarter ending Jun 30 2026, within Major Pharmaceutical Preparations Industry Quick RatioJun 30 2026 MRQ Cash & cash equivalentJun 30 2026 MRQ Current Liabilities
Royalty Pharma Plc  1.33 $ 836.986  Millions$ 630.928  Millions
Cormedix Inc   1.31 $ 256.692  Millions$ 196.535  Millions
Transcode Therapeutics Inc   1.30 $ 8.383  Millions$ 6.430  Millions
Elite Pharmaceuticals Inc   1.28 $ 39.032  Millions$ 30.442  Millions
Ani Pharmaceuticals Inc  1.27 $ 360.212  Millions$ 283.655  Millions
Pmgc Holdings Inc   1.25 $ 19.126  Millions$ 15.329  Millions
Petros Pharmaceuticals inc   1.23 $ 3.489  Millions$ 2.845  Millions
Nature s Sunshine Products inc   1.20 $ 82.503  Millions$ 68.745  Millions
Phathom Pharmaceuticals Inc   1.19 $ 182.478  Millions$ 153.777  Millions
Compass Pathways Plc  1.18 $ 433.720  Millions$ 367.285  Millions
Geovax Labs Inc   1.17 $ 3.163  Millions$ 2.712  Millions
Actuate Therapeutics Inc   1.16 $ 4.426  Millions$ 3.805  Millions
Apimeds Pharmaceuticals US, Inc.  1.16 $ 8.278  Millions$ 7.166  Millions
Emergent Biosolutions Inc   1.14 $ 139.700  Millions$ 122.800  Millions
Turn Therapeutics Inc   1.14 $ 9.958  Millions$ 8.764  Millions
Ionis Pharmaceuticals Inc   1.11 $ 350.065  Millions$ 315.638  Millions
Oramed Pharmaceuticals Inc  1.00 $ 16.091  Millions$ 16.044  Millions
Inmed Pharmaceuticals Inc  1.00 $ 2.240  Millions$ 2.235  Millions
Nkarta Inc   1.00 $ 24.958  Millions$ 24.924  Millions
Inovio Pharmaceuticals Inc   1.00 $ 36.700  Millions$ 36.678  Millions
Jazz Pharmaceuticals Plc  0.98 $ 2,199.800  Millions$ 2,239.400  Millions
Akebia Therapeutics Inc   0.97 $ 155.548  Millions$ 160.865  Millions
Syndax Pharmaceuticals Inc   0.95 $ 342.883  Millions$ 360.284  Millions
Nurix Therapeutics Inc   0.94 $ 67.840  Millions$ 72.020  Millions
Theriva Biologics inc   0.94 $ 11.337  Millions$ 12.111  Millions
Geron Corporation  0.92 $ 64.781  Millions$ 70.331  Millions
Zomedica Corp   0.84 $ 7.605  Millions$ 9.002  Millions
Cocrystal Pharma Inc   0.83 $ 2.169  Millions$ 2.616  Millions
Harrow Inc   0.82 $ 83.889  Millions$ 102.171  Millions
Cue Biopharma Inc   0.82 $ 17.414  Millions$ 21.218  Millions

Date modified: 2026-08-17T17:22:22+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.